BMS-986235

Research use only, not for human use.

BMS-986235 is a selective and orally active agonist of formyl peptide receptor 2 (FPR2) with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively.

BMS-986235 is a selective and orally active agonist of formyl peptide receptor 2 (FPR2) with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 can be used in studies about the prevention of heart failure.(In Vitro):BMS-986235 inhibits neutrophil chemotaxis and stimulats macrophage phagocytosis, thereby promoting resolution of inflammation.(In Vivo):In male C57BL/6 mice, BMS-986235 (0.3 mg/kg; p.o.) attenuates left ventricle and global cardiac remodeling after left anterior descending and reduces infarct length by 39% relative to the vehicle. BMS-986235 (1 mg/kg; p.o.) shows the Cmax, T1/2, AUC0-inf, and bioavailability (BA) values of 160 nmol/L, 0.68 hours,120 nmol/L?h, and 24%, respectively.

——

Animal Model:Male C57BL/6 miceDosage:0.3 mg/kg Administration:P.o.; daily for 24 daysResult:Left ventricle (LV) chamber remodeling is attenuated after myocardial infarction (MI). Reduced infarct length by 39% relative to vehicle.Animal Model:Male mice (BALB/cCrSlc)Dosage:1 mg/kg Administration:P.o. (Pharmacokinetic Analysis)Result:The Cmax, T1/2, AUC0-inf, and bioavailability (BA) values were 160 nmol/L, 0.68 hours, 120 nmol/L?h, and 24%, respectively.

LAR-1219

Others

Other Targets

LDL|TNF-α|Antioxidant

——

——

2253947-47-4

361.34

C18H17F2N3O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (276.75 mM)

O=C(NC=1C=CC=CC1)NC2C(=O)NCC2C=3C(F)=CC(OC)=CC3F

——

(-20℃)

With Ice Pack

≥ 2 years